BioCentury: Infectious enthusiasm - How oncolytic viruses are coming of age in cancer immunotherapy combinations
By Emily Cukier-Meisner, Senior Writer
After over two decades of scant effectiveness against cancer, oncolytic viruses could be close to finding their place in immuno-oncology combination regimens, where they could both be potentiated by and improve response rates to checkpoint agents. Meanwhile, the next generation of viruses may become more potent on their own by doubling as gene therapy vectors to enable tissue-specific delivery of therapeutic proteins and nucleic acids.
See BioCentury for more information